Wall Street analyst estimates for Vaxcyte, Inc. (PCVX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia.
Consensus price target
$122.33 (+101% vs price $60.81)
between $120.00 and $125.00 · 3 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $25.0M | $25.0M – $25.0M | -$8.23 | 6 |
| 2027E | $87.1M | $87.1M – $87.1M | -$6.50 | 6 |
| 2028E | $97.9M | $97.9M – $97.9M | -$6.44 | 6 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-2.11 | ||
| 2026-08-05 | $-1.97 | $-2.06 | +4.4% |
| 2026-05-06 | $-2.30 | $-1.78 | -29.4% |
| 2026-02-24 | $-1.80 | $-1.53 | -17.7% |
| 2025-11-04 | $-1.56 | $-1.27 | -22.8% |
| 2025-08-06 | $-1.22 | $-1.12 | -8.9% |
| 2025-05-07 | $-1.04 | $-1.02 | -2.0% |
| 2025-02-25 | $-1.02 | $-1.16 | +12.1% |
Valuation Ratios
| Price / Book | 3.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $1.0M | $1.2M | $1.4M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -$1.0M | -$1.2M | -$1.4M | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $12.8M | $30.1M | $45.6M | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | $794.3M |
| Selling, General & Admin | $5.0M | $5.4M | $7.3M | $14.6M | $25.3M | $39.8M | $60.7M | $92.9M | $129.4M |
| Operating Expenses | $17.4M | $35.5M | $52.9M | $88.2M | $103.7M | $232.3M | $468.0M | $569.5M | $923.7M |
| Operating Income | -$17.8M | -$35.5M | -$54.2M | -$89.6M | -$103.7M | -$232.3M | -$468.0M | -$569.5M | -$923.7M |
| EBITDA | -$17.2M | -$28.4M | -$49.0M | -$87.8M | -$96.6M | -$214.0M | -$392.1M | -$448.1M | -$741.8M |
| Interest Expense | 0 | $75,000 | $40,000 | $7,000 | $7,000 | $2,000 | 0 | 0 | 0 |
| Pre-tax Income | -$17.2M | -$29.5M | -$50.3M | -$89.2M | -$100.1M | -$223.5M | -$402.3M | -$463.9M | -$766.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$17.2M | -$29.5M | -$50.3M | -$89.2M | -$100.1M | -$223.5M | -$402.3M | -$463.9M | -$766.6M |
| EPS | -$4.84 | -$8.12 | -$14.10 | -$2.97 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 |
| EPS (Diluted) | -$4.83 | -$8.12 | -$14.10 | -$2.97 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 |
| Shares Outstanding (Diluted) | 3.6 M | 3.6 M | 3.8 M | 29.5 M | 51.9 M | 64.9 M | 97.2 M | 122.0 M | 136.1 M |
Price
| Price | $60.81 (closing price, November 3, 2026) |
| Market Cap | $9.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: MRNA · IBRX · PFE · GSK
Explore sector: Healthcare · Biotechnology
More sections of PCVX: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks